Building the World’s First Dedicated Drug Discovery Platform Centered on Protein Motion

Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach as an integrated team focused on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology. 

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

March 5, 2019
Relay Therapeutics To Present At Cowen 39th Annual Health Care Conference

February 6, 2019
Relay Therapeutics Names Imogen Pryce, PH.D., Vice President of Strategy and Corporate Affairs

December 20, 2018
Relay Therapeutics Secures $400 Million in Series C Financing

Read More News

Associated Team Members

Alexis Borisy

Charles Homcy, M.D.